The feasibility of using photovoice as a loneliness intervention with older Myanmar migrants.

Loneliness has detrimental physical and mental health outcomes. To date, there are few studies on loneliness interventions in lower-resource settings. Based on participatory action research methods that are theoretically informed by the social relationship expectations framework, we developed a loneliness intervention called amanane using the photovoice method with older Myanmar migrants in northern Thailand.

Risk of Cataract Surgery Complications in Patients with Prior Intravitreal Injection Therapy.

Objective: To compare the rate of cataract surgery complications in patients with and without prior intravitreal injection (IVI) pharmacotherapy.

Design: A retrospective cohort study was performed using the TriNetX (Cambridge, MA) aggregated electronic health records research network.

Subjects: Patients with a history of IVI therapy within twenty years of cataract surgery were compared to a control group using propensity score matching (PSM) to balance for baseline demographics, systemic, and ocular co-morbidities.

Quantity of Caloric Support After Pediatric Severe Traumatic Brain Injury: Description of Associated Outcomes in a Single Retrospective Center Cohort, 2010-2022.

Objectives: To examine the relationship between adequacy of caloric nutritional support during the first week after severe traumatic brain injury (TBI) and outcome.

Design: Single-center retrospective cohort, 2010-2022.

Setting: Tertiary care children's hospital with a level 1 trauma center.

Neutrophil-to-Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma.

Objective: To determine the relationship between pretreatment neutrophil-to-lymphocyte ratio (NLR) and 6-month progression-free survival (PFS)/2-year overall survival (OS) among patients with recurrent or metastatic (R/M) oral cavity cancer on pembrolizumab.

Study Design: This study was a retrospective, observational study performed at a tertiary care academic center.

Setting: Participants included patients with oral cavity squamous cell carcinoma (OCSCC) who began pembrolizumab treatment at the University of California, San Francisco between May 2016 and May 2022.